Drugs / interleukin-3
interleukin-3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00002258 | — | HIV infectious disease | Sandoz | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00005787 Background | Sep 1999 → Jan 2002 | lymphoma, neutropenia | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00006225 Background | Nov 1999 → Jan 2004 | breast cancer, leukemia, myelodysplastic/myeloproliferative disease, plasma cell neoplasm | Northwestern University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interleukin-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006225 ↗ |
| Known as | RhIL-3 | “SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3)” NCT00002258 ↗ |
| Known as | SDZ ILE-964 | “SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3)” NCT00002258 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Interleukin-3” NCT00002258 ↗ |
| Route | Subcutaneous | “administered by daily subcutaneous injections” NCT00002258 ↗ |